Publications

In Vitro Activity of the Extended-Spectrum β-Lactamase Inhibitor Enmetazobactam (formerly AAI101), in Combination with Cefepime, against 90 Moleculary Characterized Enterobacteriaceae Isolates Expressing a Variety of Non-β-Lactam Resistance Mechanisms. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1170

Antimicrobial Activity of Cefoperazone-Sulbactam Tested against Gram-Negative Organisms from Europe, Asia-Pacific, and Latin America in 2015-2016. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1199

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Patients at Risk of Infections Caused by Resistant Gram-Negative Pathogens. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1191

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centres in Europe and the Asia-Pacific Region (2018). Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1174

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against European Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1189

Cefepime-Zidebactam (WCK 5222) Activity When Tested against Gram-Negative Organisms Isolated from Patients Hospitalized in Europe and the Asia-Pacific Region in 2018. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1172

Activity of Meropenem-Vaborbactam and Single-Agent Comparators against KPC-Producing Enterobacterales Isolates from European Countries (2016-2018) Stratified by Infection Type. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#L0041

In vitro activity of tedizolid against gram-positive cocci isolates from patients hospitalized with pneumonia in the United States and Europe, 2014-2016. by Bensaci M, Tan C, Pfaller MA and Mendes RE published in Journal Infect Diseases and Treatment. 2018; 4 (1): 2

In vitro activity of isavuconazole versus opportunistic fungal pathogens from two mycology reference laboratories. by Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, Mele J, Kovanda LL and Castanheira M published in Antimicrob Agents Chemother. 2018; 62 (10): e01230

In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016). by Duncan LR, flamm RK, Sader HS and Mendes RE published in Diagn. Microbiol. Infect. Dis.: in press, 2018.

Trends in Antimicrobial Nonsusceptibility of PCV13-Type Streptococcus pneumoniae Pneumonia in Adults in the United States during 2009-2017. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1444

Comparison of Ceftazidime-Avibactam and Ceftolozane-Tazobactam In Vitro Activities when Tested against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2017). Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA USA
#2427

Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Clinical Trial Anaerobic Isolates. Lead author: D Shortridge, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#2373

Activity of a Long-Acting Echinocandin Rezafungin Tested against Invasive Fungal Isolates Collected Worldwide. Lead author: M Castanheira, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#2400

Antimicrobial Activity of Dalbavancin Tested against Gram-Positive Organisms Isolated from Patients with Infective Endocarditis in United States and European Medical Centers. Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1081

Comparative Activity of Plazomicin and Other Aminoglycosides against Enterobacteriaceae Isolates from Various Infection Sources from Hospitalized Patients in the United States. Lead author: M Castanheira, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1345

Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1364

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) Gram-Negative Isolates from Patients with Pneumonia in US Medical Centers. Lead author: SJR Arends, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1485

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections: Results from the International Network for Optimal Resistance Monitoring (INFORM) Program. Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1523

Omadacycline In Vitro Activity against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1377

Global Surveillance: Susceptibility of Ceftolozane-Tazobactam against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa Isolates Collected from Bloodstream Infections in the United States from 2015-2017. Lead author: SJR Arends, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1047

Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program. Lead author: HS Sader, presented at ID Week 2018, October 3-7, San Francisco, CA, USA.
#1000

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bloodstream Infections in United States Medical Centers (2015-2017). Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA USA
#1004

Analyses of a ceftazidime-avibactam-resistant Citrobacter freundii isolate carrying bla_kpc-2 reveals a heterogenous population and reversible genotype. by Castanheira M, Arends SJR, Davis AP, Woosley LN, Bhalodi AA and MacVane SH published in MSphere. 2018; 3 (5): e00408

Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M. Antimicrob. Agents Chemother.: in press, 2018.

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. by Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M and Jain R. published in Infect Drug Resist. 2018; 2018 (11): 1499-1510

Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. by Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM and Flamm RK. published in J. Antimicrob. Chemother.: in press, 2018.

Analysis of Oritavancin In Vitro Activity against Enterococcal Isolates from US Medical Centers and Resistant Subsets. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal
#116

Activity of Meropenem-Vaborbactam and Comparator Agents against Multidrug-Resistant Enterobacteriaceae Isolates from the United States Analyzed by Site of Infection. Lead author: M Castanheira, presented at ESMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#117

Spectrum of Activity of RX-P2382, a Novel Class of Bacterial Ribosome Inhibitor. Lead author: D Shortridge, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#46

Tedizolid In Vitro Activity against a Contemporary Challenge Collection of Multidrug-Resistant Enterococcal Clinical Isolates. Lead author: CG Carvalhaes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#111

In Vitro Activity Evaluation of a Next-Generation Polymyxin, SPR206, against Non-Fermentative Gram-Negative Bacilli Responsible for Human Infections. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#80

Activity of an Investigational Polymyxin-B-Like Compound (SPR206) against a Set of Enterobacteriaceae Organisms Responsible for Human Infections. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#81

The Role of Whole Genome Sequencing on Post-Marketing Surveillance Programs: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam in the United States. Lead author: H Sader, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#107

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. by Sader HS, Flamm RK, Dale GE, Rhomberg PR and Castanheira M published in J Antimicrob Chemother. 2018; 73: 2400-2404

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. by Pfaller MA, Mendes RE, Duncan LR, Flamm RK and Sader HS. published in J. Antimicrob. Chemother. 2018; 73 (10) 2748-2756

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). by Sader HS, Castanheira M, Mendes RE and Flamm RK published in J. Antimicrob. Chemother.: in press, 2018.

Delafloxacin in vitro broth microdilution and disk diffusion antimicrobial susceptibility testing guidelines: Susceptibility breakpoint criteria and quality control ranges for an expanded spectrum anionic fluoroquinolone. by Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D and Jones RN published in J. Clin. Microbiol. 2018; 56 (8): e00339

Disruption of mgrB and Alterations on pmrB Are Most Common Resistance Mechanisms among Colistin-Resistance among Klebsiella pneumoniae from a Global Surveillance Program. Lead author: M Castanheira, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-467

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-393

Global Trends in Prevalence and Diversity of Carbapenemases Carrying Enterobacteriaceae Identified through SENTRY Antimicrobial Surveillance Program. Lead author: LM Deshpande, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-404https://www.jmilabs.com/wp-admin/post.php?post=6561&action=edit#

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Multidrug-Resistant Streptococcus pneumoniae (2014-2017): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-397

Antimicrobial Activity of the Novel Siderophore Cehpalosporin GT-1 Tested Alone and Combined with the β-Lactamase Inhibitor GT-055 against Molecularly Characterized Enterobacteriaceae Clinical Isolates. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-571

Antimicrobial Activity Assessment of Tebipenem (SPR859) against an Isolate Collection Causing Urinary Tract Infections. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-560

Antimicrobial Activity of Ceftobiprole When Tested against Gram-Positive Cocci Causing Serious Infections (2016-2017): Endocarditis, Diabetic Foot, and Bone/Joint Infections. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-581

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by United States Census Divisions: Results from the 2017 INFORM Program. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA.
# Sunday-388

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Isolates Collected from Hematology or Oncology Patients in Europe during 2011-2017 as Part of a Global Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-394

Antimicrobial Activity of Tebipenem (SPR859) against a Global Challenge Set of Enterobacteriaceae Isolates. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-558

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) Gram-Negative Isolates from Intensive Care Unit Patients with Pneumonia in US Medical Centers. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-392

The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. Lead author: DJ Diekema, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-400